October, 2024 Biparetide DSS IBD in vivo data presented as a poster at the European Gastroenterology Conference
At the European Gastroenterology Conference in Vienna in October 2024, Phoenixlab and Novapep presented a poster with key data from Biparetide in the DSS IBD model. The two of the key figures in the poster were:
September, 2024 - Novapep secures $500k of funding to develop novel anti-inflammatory peptide
Novapep Pty Ltd is pleased to announce it recently closed a $500k SAFE Note funding round. The investment was led by a syndicate of Sydney Angels members for $250k, with previous investors including the University of Sydney contributing the balance.
Novapep is a pre-clinical stage Australian/US biotech company developing a novel peptide, biparetide, to treat inflammatory diseases such as atopic dermatitis, inflammatory bowel disease, and cerebral malaria; diseases which afflict many people around the world. Biparetide is being developed as a prescription drug for treating these diseases as it is stable and suitable for topical and oral use. It avoids the side-effects of existing therapies, which may enable patients to use it continuously to achieve lasting relief.
Biparetide was invented, patented, and licensed exclusively to Novapep by co-founder Professor John Griffin of the Scripps Research Institute in the USA. Biparetide is a mimetic of 3K3A-Activated Protein C (APC), an earlier invention of Professor Griffin.
The funds raised by Novapep in this current equity round will be used to complete pre-clinical studies of biparetide by global experts in each of the following fields:
Inflammatory Bowel Disease: Professor Silvio Danese (San Raffaele, Milan) is undertaking a dextran sulphate sodium anti-inflammatory study.
Sepsis: Professor Yugeesh is undertaking an E. Coli rat model of survival.
Parties interested in the potential of Biparetide should contact Jay Hennock, CEO of Novapep Pty Ltd, for further information at jay.hennock@novapep.com.
July, 2024 Prof John Griffin's Biparetide/G10 paper published in the Journal of Thrombosis and Hemostatis
An orthosteric/allosteric bivalent peptide agonist comprising covalently linked protease-activated receptor-derived peptides mimics in vitro and in vivo activities of activated protein C
Biparetide(“G10”) reduced murine death from i.p. endotoxin/LPS. Survival improved from 31% to 53% with only one i.v. dose of 2 mg/kg at 4 hours after LPS
